Article 2: EVALUATION OF THE GASTRO-PROTECTIVE POTENTIAL OF Archachatina Marginata MUCIN IN ALBINO RAT (Vol. 1, Iss. 2; pp. 96-102)

Amah, A.K, Ewa, O Ejiofor, D.C, Opara, J, Wassagwa, J

Text | Abstract | PDF

EVALUATION OF THE GASTRO-PROTECTIVE POTENTIAL OF Archachatina Marginata MUCIN IN ALBINO RAT

           

1Amah, A.K, 2Ewa, O 1Ejiofor, D.C, 3Opara, J, 4Wassagwa, J

1Department of Human physiology, Imo State University, Owerri, Nigeria

2Department of Biochemistry, Ahmadu Bello University, Zaria Nigeria.

3Department of Biochemistry, Gregory University, Uturu Abia State, Nigeria.

Corresponding author: *Ewa Ogbonnaya

Email: ewahalfred@gmail.com  

 

 

A R T I C L E  I N F O

Article Type: Research

Received: 24, Sep. 2018.

Accepted: 27, Oct. 2018.

Published: 30, Oct. 2018.

 

 

 A B S T R A C T

Gastro-protective potential of A. marginata mucin in albino Rats was evaluated by standard procedures. Oral administration of indomethacin caused ulceration at the glandular region of the stomach which was characterized by a significantly high ulcer index (8.52±0.82). However, pretreatment with mucin prior to oral administration of indomethacin significantly reduced ulcer index in a dose-dependent manner in which (3.00±0.35) was recorded on 800mg/kg mucin. This observation was consolidated by the results generated on the percentage ulcer inhibitory analysis carried out on mucin which also was found to be dose dependent with 80% inhibition being recorded following the administration of 800mg/kg of mucin. Gastric mucus was significantly reduced in the negative control group (0.21±0.04) compared to the normal control group (0.42±0.10). However, it was significantly increased in groups pretreated with 400 and 800mg/kg mucin (0.29±0.05), (0.31±0.07) respectively. It can be deduced from the findings made in this study that mucin derived from A. marginata has gastroprotective potential and hence should be considered for inclusion in the formulation of non-steroidal anti-inflammatory drugs to either reduce or mask its natural potential to cause mucosal injury.
Keywords:

Archachatina marginata, mucin, gastric ulcer, GIT.

References

  1. Abdulla, A., Adams, N., Bone, M., Elliott, A.M., Gaffin, J., Jones, D. (2013). Guidance on the management of pain in older people. Age Ageing, 42(1): 11 -57.
  2. Abere, S.A and Lameed, G.A.(2008). The medicinal utilization of snails in some selected states in Nigeria. In:Proceeding of the first National conference of the Forests and Forest Products Society of Nigeria, 233–237.
  3. Adikwu, M.U and Enebeke, T.C. (2007). Evaluation of snail mucin dispersed in Brachystegia eurocoma gum gel as a wound healing agent. Animal Research International, 4(2), 683-690.
  4. Adikwu, M.U and Ikejiuba, C.C. (2005). Some physicochemical and wound healing properties of snail mucin. Bollettino Chimico Farmaceutico, 145(2), 5.
  5. Adiukwu, M.U. (2005). Evaluation of snail mucin motif as rectal absorption enhancer for insulin in non-diabetic rat model. Biopharmaceutical Bull, 28(9), 18011-1804.
  6. Corne, S.J., Morrissey, S.M and Wood, R.J. (1974). A method for the quantitative estimation of gastric barrier mucus. London Journal of physiology, 242, 116-117.
  7. Germano, D.C and Elisabetta,C.(2015). The Use of NSAIDs in the Postoperative Period: Advantage and Disadvantages. Journal of Anesthesia and Critical Care, 3: 4.
  8. Glade, M.J. (1990). Polysulphated glycoaminoglycan accelerate net synthesis of collagen and glycosaminoglycans by arthritics equine cartilage tissues and chondrocytes. American Journal of Vertinary Research, 51,779-785.
  9. Grosser T, Fries T, Fitzgerald, G.A (2006). Biological basis for cardiovascular consequences of COX2 inhibition: Therapeutic challenges and opportunities. Journal of Clinical. Investigation; 116 (1):4-15.
  10. Hano, J., Bogajski, J., Danek, L and Wantuch, C1976). The effect of neuroleptic development of gastric ulcers in rats exposed to restraint cold stress. Journal of Pharmacology, 32(54), 23-25.
  11. Jiang, T., Tang, C.P., Chen, Y.F., Feng, Y.F., Chu, B., He, J.J., Chen, Q.Y.(2009). Officinarum flavonoids’ influence on rat gastric ulcer model. Herbal Medicine., 32(2), 261.
  12. Larkai, E.N., Smith, J.L., Lidsky, M.D.(1987).Gastroduodenal mucosa and dyspeptic arthritic patients during chronic nonsteroidal anti-inflammatory drug use. American Journal of Gastroenterology, (82).
  13. Lorke D. (1983). New approach to practical acutetoxicity. Archives of Toxicology, 6(13),
  14. McGettigan P, Henry D. (2011). Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observation studies. PLos Med. 8 🙁 9):e100198.
  15. Onder, G., Pellicciotti, F., Gambassi, G., Bernabei, R.(2004). NSAID-related psychiatric adverse events: who is at risk? Drugs, 64: 2619-2627.
  16. Pilotto, A., Franceschi, M., Leandro, G.Di., Mario. F.(2003). NSAID and aspirin use by the elderly in general practice: effect on gastrointestinal symptoms and therapies. Drugs Aging, 20: 701 -710
  17. Sarges,P., Steinberg, J. M and Lewis, J. H. (2016). Drug-induced liverinjury: highlights from a review of the 2015 literature, Drug Safety, 39 :(. 9).801–821.
  18. Scheiman, J.M and Fendrick, A.M.(2005). Practical approaches to minimizing gastrointestinal and cardiovascular safety concerns with COX-2 inhibitors and NSAIDs. Arthritis Res Ther, 7, 23-29.
  19. Techman, A. (2007). Novartis Withdraws Lumiracoxib (Prexigeń) in Australia in Response to Decision From Terapeutic Goods Administration to Cancel Registration,” C IAO Med.
  20. Urushidani, T., Kasuya, Y and Okabe, S .(1979). The mechanism of aggravation of indomethacin induced gastric ulcers by adrenalectomy in rats. Japan Journal of Pharmacology, 12(29), 775-778.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.